Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Sex differences in the phagocytic and migratory activity of microglia and their impairment by palmitic acid.

Yanguas-Casás N, Crespo-Castrillo A, de Ceballos ML, Chowen JA, Azcoitia I, Arevalo MA, Garcia-Segura LM.

Glia. 2018 Mar;66(3):522-537. doi: 10.1002/glia.23263. Epub 2017 Nov 15.

PMID:
29139169
2.

Boosting brain glucose metabolism to fight neurodegeneration?

de Ceballos ML, Köfalvi A.

Oncotarget. 2017 Feb 28;8(9):14273-14274. doi: 10.18632/oncotarget.15131. No abstract available.

3.

Effects of Video Game Training on Behavioral and Electrophysiological Measures of Attention and Memory: Protocol for a Randomized Controlled Trial.

Ballesteros S, Mayas J, Ruiz-Marquez E, Prieto A, Toril P, Ponce de Leon L, de Ceballos ML, Reales Avilés JM.

JMIR Res Protoc. 2017 Jan 24;6(1):e8. doi: 10.2196/resprot.6570.

4.

The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis.

Pérez-Domper P, Palomo V, Gradari S, Gil C, de Ceballos ML, Martínez A, Trejo JL.

Neuropharmacology. 2017 Apr;116:174-187. doi: 10.1016/j.neuropharm.2016.12.019. Epub 2016 Dec 22.

PMID:
28012947
5.

Vascular Dysfunction in a Transgenic Model of Alzheimer's Disease: Effects of CB1R and CB2R Cannabinoid Agonists.

Navarro-Dorado J, Villalba N, Prieto D, Brera B, Martín-Moreno AM, Tejerina T, de Ceballos ML.

Front Neurosci. 2016 Sep 16;10:422. eCollection 2016.

6.

Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes.

Pajares M, Jiménez-Moreno N, García-Yagüe ÁJ, Escoll M, de Ceballos ML, Van Leuven F, Rábano A, Yamamoto M, Rojo AI, Cuadrado A.

Autophagy. 2016 Oct 2;12(10):1902-1916. Epub 2016 Jul 18.

7.

Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease.

Köfalvi A, Lemos C, Martín-Moreno AM, Pinheiro BS, García-García L, Pozo MA, Valério-Fernandes Â, Beleza RO, Agostinho P, Rodrigues RJ, Pasquaré SJ, Cunha RA, de Ceballos ML.

Neuropharmacology. 2016 Nov;110(Pt A):519-529. doi: 10.1016/j.neuropharm.2016.03.015. Epub 2016 Mar 11.

8.

Preliminary research on 1-(4-bromo-2-nitroimidazol-1-yl)-3-[(18)F]fluoropropan-2-ol as a novel brain hypoxia PET tracer in a rodent model of stroke.

Nieto E, Delgado M, Sobrado M, de Ceballos ML, Alajarín R, García-García L, Kelly J, Lizasoain I, Pozo MA, Álvarez-Builla J.

Eur J Med Chem. 2015 Aug 28;101:604-15. doi: 10.1016/j.ejmech.2015.06.023. Epub 2015 Jun 12.

PMID:
26204508
9.

Normal aging in rats and pathological aging in human Alzheimer's disease decrease FAAH activity: modulation by cannabinoid agonists.

Pascual AC, Martín-Moreno AM, Giusto NM, de Ceballos ML, Pasquaré SJ.

Exp Gerontol. 2014 Dec;60:92-9. doi: 10.1016/j.exger.2014.10.011. Epub 2014 Oct 18.

PMID:
25456842
10.

Leptin gene therapy attenuates neuronal damages evoked by amyloid-β and rescues memory deficits in APP/PS1 mice.

Pérez-González R, Alvira-Botero MX, Robayo O, Antequera D, Garzón M, Martín-Moreno AM, Brera B, de Ceballos ML, Carro E.

Gene Ther. 2014 Mar;21(3):298-308. doi: 10.1038/gt.2013.85. Epub 2014 Jan 16.

PMID:
24430238
11.

Leptin regulates glutamate and glucose transporters in hypothalamic astrocytes.

Fuente-Martín E, García-Cáceres C, Granado M, de Ceballos ML, Sánchez-Garrido MÁ, Sarman B, Liu ZW, Dietrich MO, Tena-Sempere M, Argente-Arizón P, Díaz F, Argente J, Horvath TL, Chowen JA.

J Clin Invest. 2012 Nov;122(11):3900-13. doi: 10.1172/JCI64102. Epub 2012 Oct 15.

12.

Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice.

Martín-Moreno AM, Brera B, Spuch C, Carro E, García-García L, Delgado M, Pozo MA, Innamorato NG, Cuadrado A, de Ceballos ML.

J Neuroinflammation. 2012 Jan 16;9:8. doi: 10.1186/1742-2094-9-8.

13.

Impaired hippocampal glucoregulation in the cannabinoid CB1 receptor knockout mice as revealed by an optimized in vitro experimental approach.

Lemos C, Valério-Fernandes A, Ghisleni GC, Ferreira SG, Ledent C, de Ceballos ML, Köfalvi A.

J Neurosci Methods. 2012 Mar 15;204(2):366-73. doi: 10.1016/j.jneumeth.2011.11.028. Epub 2011 Dec 6.

PMID:
22155442
14.

Molecular reorganization of endocannabinoid signalling in Alzheimer's disease.

Mulder J, Zilberter M, Pasquaré SJ, Alpár A, Schulte G, Ferreira SG, Köfalvi A, Martín-Moreno AM, Keimpema E, Tanila H, Watanabe M, Mackie K, Hortobágyi T, de Ceballos ML, Harkany T.

Brain. 2011 Apr;134(Pt 4):1041-60. doi: 10.1093/brain/awr046.

15.

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease.

Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML.

Mol Pharmacol. 2011 Jun;79(6):964-73. doi: 10.1124/mol.111.071290. Epub 2011 Feb 24.

16.

Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease.

Rojo AI, Innamorato NG, Martín-Moreno AM, De Ceballos ML, Yamamoto M, Cuadrado A.

Glia. 2010 Apr;58(5):588-98. doi: 10.1002/glia.20947.

PMID:
19908287
17.

Central levodopa influx and the clinical motor response to levodopa in patients with Parkinson disease complicated with motor fluctuations and dyskinesias.

López-Ariztegui N, Arévalo MA, de Ceballos ML, Grandas F.

Clin Neuropharmacol. 2009 Nov-Dec;32(6):321-5. doi: 10.1097/WNF.0b013e3181b40378.

PMID:
19667975
18.

The transcription factor Nrf2 is a therapeutic target against brain inflammation.

Innamorato NG, Rojo AI, García-Yagüe AJ, Yamamoto M, de Ceballos ML, Cuadrado A.

J Immunol. 2008 Jul 1;181(1):680-9.

19.

Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions.

De March Z, Zuccato C, Giampà C, Patassini S, Bari M, Gasperi V, De Ceballos ML, Bernardi G, Maccarrone M, Cattaneo E, Fusco FR.

Neuroscience. 2008 Mar 27;152(3):734-40. doi: 10.1016/j.neuroscience.2007.11.044. Epub 2007 Dec 8.

PMID:
18313855
20.

Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.

Darmopil S, Muñetón-Gómez VC, de Ceballos ML, Bernson M, Moratalla R.

Eur J Neurosci. 2008 Feb;27(3):580-92. doi: 10.1111/j.1460-9568.2008.06040.x.

PMID:
18279311
21.

Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML.

J Neurosci. 2005 Feb 23;25(8):1904-13.

22.

Functional responses to the cannabinoid agonist WIN 55,212-2 in neonatal rats of both genders: influence of weaning.

Borcel E, Pérez-Alvarez L, de Ceballos ML, Ramirez BG, Marco EM, Fernández B, Rubio M, Guaza C, Viveros MP.

Pharmacol Biochem Behav. 2004 Jul;78(3):593-602.

PMID:
15251268
23.

Beta-amyloid25-35 inhibits glutamate uptake in cultured neurons and astrocytes: modulation of uptake as a survival mechanism.

Fernández-Tomé P, Brera B, Arévalo MA, de Ceballos ML.

Neurobiol Dis. 2004 Apr;15(3):580-9.

PMID:
15056466
24.

Synthesis of glycosyl derivatives as dopamine prodrugs: interaction with glucose carrier GLUT-1.

Fernández C, Nieto O, Fontenla JA, Rivas E, de Ceballos ML, Fernández-Mayoralas A.

Org Biomol Chem. 2003 Mar 7;1(5):767-71.

PMID:
12929357
25.

Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway.

Gómez Del Pulgar T, De Ceballos ML, Guzmán M, Velasco G.

J Biol Chem. 2002 Sep 27;277(39):36527-33. Epub 2002 Jul 19.

26.
27.

Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.

Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fernández-Ruiz JJ.

Eur J Neurosci. 2001 Dec;14(11):1827-32.

PMID:
11860478
28.

Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.

Sánchez C, de Ceballos ML, Gomez del Pulgar T, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramón y Cajal S, Guzmán M.

Cancer Res. 2001 Aug 1;61(15):5784-9.

29.

beta-Amyloid-induced cytotoxicity, peroxide generation and blockade of glutamate uptake in cultured astrocytes.

de Ceballos ML, Brera B, Fernández-Tomé MP.

Clin Chem Lab Med. 2001 Apr;39(4):317-8.

30.

beta-amyloid peptides are cytotoxic to astrocytes in culture: a role for oxidative stress.

Brera B, Serrano A, de Ceballos ML.

Neurobiol Dis. 2000 Aug;7(4):395-405.

PMID:
10964610
31.

Repeated intracerebroventricular administration of beta-amyloid(25-35) to rats decreases muscarinic receptors in cerebral cortex.

Pavía J, Alberch J, Alvárez I, Toledano A, de Ceballos ML.

Neurosci Lett. 2000 Jan 7;278(1-2):69-72.

PMID:
10643803
32.

The AMP-activated protein kinase is involved in the regulation of ketone body production by astrocytes.

Blázquez C, Woods A, de Ceballos ML, Carling D, Guzmán M.

J Neurochem. 1999 Oct;73(4):1674-82.

33.
34.

In vivo effects of new inhibitors of catechol-O-methyl transferase.

Rivas E, de Ceballos ML, Nieto O, Fontenla JA.

Br J Pharmacol. 1999 Apr;126(7):1667-73.

35.

Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins.

Pavía J, de Ceballos ML, Sanchez de la Cuesta F.

Fundam Clin Pharmacol. 1998;12(5):473-81. Review.

PMID:
9794144
36.

Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease.

Fernandez A, de Ceballos ML, Rose S, Jenner P, Marsden CD.

Brain. 1996 Jun;119 ( Pt 3):823-30.

37.

Synthesis and affinities for dopamine (D2) and 5-hydroxytryptamine (5-HT2A) receptors of 1-(benzoylpropyl)-4-(1-oxocycloalkyl-2-ethyl)-piperazines as cyclic butyrophenone derivatives.

Raviña E, Fueyo J, Masaguer CF, Negreira J, Cid J, Loza I, Honrubia A, Tristán H, G-Ferreiro T, Fontenla JA, Rosa E, Calleja JM, De Ceballos ML.

Chem Pharm Bull (Tokyo). 1996 Mar;44(3):534-41.

PMID:
8882450
38.

Muscarinic receptors in Alzheimer's disease.

Pavía J, de Ceballos ML, Sánchez de la Cuesta F.

Methods Find Exp Clin Pharmacol. 1996;18 Suppl B:71-5. No abstract available.

PMID:
8899700
39.
40.

Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients.

Fernandez A, de Ceballos ML, Jenner P, Marsden CD.

Neuroscience. 1994 Jul;61(1):73-9.

PMID:
7969897
41.

Parallel alterations in Met-enkephalin and substance P levels in medial globus pallidus in Parkinson's disease patients.

de Ceballos ML, Fernandez A, Jenner P, Marsden CD.

Neurosci Lett. 1993 Oct 1;160(2):163-6.

PMID:
7504224
42.

Synthesis and inhibitory activities against enkephalin degrading aminopeptidase of H-Trp(Nps)-Lys-OMe analogues bearing chelating groups.

González-Muñiz R, Harto JR, de Ceballos ML, del Río J, García-López MT.

Arch Pharm (Weinheim). 1992 Dec;325(12):743-9.

PMID:
1489252
43.

Striatal neuropeptide levels in Parkinson's disease patients.

Fernandez A, de Ceballos ML, Jenner P, Marsden CD.

Neurosci Lett. 1992 Oct 12;145(2):171-4.

PMID:
1281532
44.

Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.

Taylor MD, De Ceballos ML, Rose S, Jenner P, Marsden CD.

Eur J Pharmacol. 1992 Aug 25;219(2):183-92.

PMID:
1385171
45.

Aminopeptidase inhibitory properties and analgesic activity of (2S,3R)-3,7-diamino-2-hydroxy-heptanoic acid containing tripeptide analogues of the N-terminal tripeptide of probestin.

Herranz R, Vinuesa S, Pérez C, García-López MT, De Ceballos ML, Murillo FM, del Río J.

Arch Pharm (Weinheim). 1992 Aug;325(8):515-8.

PMID:
1417460
46.

Analgesic dipeptide derivatives. 7. 3,7-Diamino-2-hydroxyheptanoic acid (DAHHA) containing dipeptide analogues of the analgesic compound H-Lys-Trp(Nps)-OMe.

Herranz R, Vinuesa S, Pérez C, García-López MT, López E, de Ceballos ML, Del Río J.

J Med Chem. 1992 Mar 6;35(5):889-95.

PMID:
1347791
47.

Prolonged antinociceptive activity of pseudodipeptide analogues of Lys-Trp(Nps) and Trp(Nps)-Lys.

de Ceballos ML, Lopez AE, Harto JR, Bravo A, Gomez-Monterrey I, Gonzalez-Muñiz R, Garcia-Lopez MT, del Rio J.

Peptides. 1992 Jan-Feb;13(1):63-7.

PMID:
1620657
48.

Synthesis and inhibitory activities against aminopeptidase B and enkephalin-degrading enzymes of ketomethylene dipeptide analogues of arphamenines.

García-López MT, González-Muñiz R, Hartoa JR, Gómez-Monterrey I, Pérez C, De Ceballos ML, López E, Del Río J.

Arch Pharm (Weinheim). 1992 Jan;325(1):3-8.

PMID:
1605710
49.

Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset.

Pérez-Otaño I, Herrero MT, Oset C, De Ceballos ML, Luquin MR, Obeso JA, Del Río J.

Brain Res. 1991 Dec 13;567(1):127-32.

PMID:
1815820
50.

Isocratic reverse-phase HPLC separation and RIA used in the analysis of neuropeptides in brain tissue.

De Ceballos ML, Taylor MD, Jenner P.

Neuropeptides. 1991 Nov;20(3):201-9.

PMID:
1722286

Supplemental Content

Loading ...
Support Center